Daniel C O's most recent trade in Acumen Pharmaceuticals Inc was a trade of 9,346 Common Stock done at an average price of $1.8 . Disclosure was reported to the exchange on Jan. 21, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Acumen Pharma Inc | Daniel O'Connell | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.81 per share. | 21 Jan 2026 | 9,346 | 883,964 | - | 1.8 | 16,927 | Common Stock |
| Acumen Pharma Inc | Daniel O'Connell | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.88 per share. | 21 Jan 2026 | 2,689 | 881,275 | - | 1.9 | 5,066 | Common Stock |
| Acumen Pharma Inc | Daniel O'Connell | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2026 | 450,000 | 450,000 | - | - | Employee Stock Option (right to buy) | |
| Acumen Pharma Inc | Daniel O'Connell | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2026 | 299,800 | 893,310 | - | 0 | Common Stock | |
| Acumen Pharma Inc | Daniel O'Connell | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.76 per share. | 08 Jan 2026 | 12,941 | 598,898 | - | 1.8 | 22,832 | Common Stock |
| Acumen Pharma Inc | Daniel O'Connell | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.82 per share. | 08 Jan 2026 | 8,143 | 611,839 | - | 1.8 | 14,815 | Common Stock |
| Acumen Pharma Inc | Daniel O'Connell | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.73 per share. | 08 Jan 2026 | 5,388 | 593,510 | - | 1.7 | 9,307 | Common Stock |
| Acumen Pharma Inc | Daniel O'Connell | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.99 per share. | 05 Jan 2026 | 37,755 | 619,982 | - | 2.0 | 74,981 | Common Stock |
| Acumen Pharma Inc | Daniel O'Connell | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.97 per share. | 05 Jan 2026 | 5,102 | 657,737 | - | 2.0 | 10,032 | Common Stock |
| Acumen Pharma Inc | Daniel O'Connell | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.97 per share. | 05 Jan 2026 | 4,649 | 662,839 | - | 2.0 | 9,163 | Common Stock |
| Synchrony Financial | Daniel O. Colao | Director | Grant, award, or other acquisition of securities at price $ 83.43 per share. | 31 Dec 2025 | 660 | 3,972 (0%) | 0% | 83.4 | 55,064 | Common Stock |
| Synchrony Financial | Daniel O. Colao | Director | Grant, award, or other acquisition of securities at price $ 70.47 per share. | 17 Nov 2025 | 15 | 3,312 (0%) | 0% | 70.5 | 1,057 | Dividend Equivalent Unit |
| Synchrony Financial | O. Daniel Colao | Director | Grant, award, or other acquisition of securities at price $ 71.05 per share. | 30 Sep 2025 | 775 | 3,297 (0%) | 0% | 71.1 | 55,064 | Common Stock |
| Synchrony Financial | Daniel O. Colao | Director | Grant, award, or other acquisition of securities at price $ 71.45 per share. | 15 Aug 2025 | 11 | 2,522 (0%) | 0% | 71.5 | 786 | Dividend Equivalent Unit |
| Synchrony Financial | Daniel O. Colao | Director | Grant, award, or other acquisition of securities at price $ 66.74 per share. | 30 Jun 2025 | 825 | 2,511 (0%) | 0% | 66.7 | 55,061 | Common Stock |
| W & T Offshore Inc | Daniel O. Conwill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 103,448 | 103,448 | - | - | Restricted Stock Units | |
| W & T Offshore Inc | Daniel O. Conwill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2025 | 73,892 | 0 | - | - | Restricted Stock Units | |
| W & T Offshore Inc | Daniel O. Conwill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2025 | 73,892 | 147,628 (0%) | 0% | - | Common Stock | |
| Synchrony Financial | Daniel O. Colao | Director | Grant, award, or other acquisition of securities at price $ 60.44 per share. | 15 May 2025 | 9 | 1,686 (0%) | 0% | 60.4 | 544 | Dividend Equivalent Unit |
| Synchrony Financial | Daniel O. Colao | Director | Grant, award, or other acquisition of securities at price $ 52.94 per share. | 31 Mar 2025 | 1,039 | 1,677 (0%) | 0% | 52.9 | 55,005 | Common Stock |
| Synchrony Financial | Daniel O. Colao | Director | Grant, award, or other acquisition of securities at price $ 65.33 per share. | 18 Feb 2025 | 3 | 638 (0%) | 0% | 65.3 | 196 | Dividend Equivalent Unit |
| Acumen Pharma Inc | Daniel O'Connell | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.59 per share. | 21 Jan 2025 | 12,619 | 667,488 | - | 1.6 | 20,102 | Common Stock |
| Acumen Pharma Inc | Daniel O'Connell | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 338,000 | 338,000 | - | - | Employee Stock Option (right to buy) | |
| Acumen Pharma Inc | Daniel O'Connell | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 225,400 | 680,107 | - | 0 | Common Stock | |
| Acumen Pharma Inc | Daniel O'Connell | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.84 per share. | 03 Jan 2025 | 47,778 | 454,707 | - | 1.8 | 87,873 | Common Stock |
| Synchrony Financial | Daniel O. Colao | Director | Grant, award, or other acquisition of securities at price $ 65.01 per share. | 31 Dec 2024 | 635 | 635 (0%) | 0% | 65.0 | 41,281 | Common Stock |
| W & T Offshore Inc | Daniel O. Conwill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 73,892 | 73,892 | - | - | Restricted Stock Units | |
| W & T Offshore Inc | Daniel O. Conwill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 38,760 | 0 | - | - | Restricted Stock Units | |
| W & T Offshore Inc | Daniel O. Conwill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 38,760 | 73,736 (0%) | 0% | - | Common Stock | |
| Acumen Pharma Inc | O'Connell Daniel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 3.47 per share. | 19 Jan 2024 | 15,200 | 502,485 | - | 3.5 | 52,753 | Common Stock |
| Seelos Therapeutics Inc | J. Daniel O'Connor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 1,666 | 1,666 | - | - | Stock Option (right to buy) | |
| Acumen Pharma Inc | O'Connell Daniel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 602,000 | 602,000 | - | - | Employee Stock Option (right to buy) | |
| Acumen Pharma Inc | Daniel O'Connell | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 401,000 | 517,685 | - | 0 | Common Stock | |
| W & T Offshore Inc | Daniel O. Conwill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 38,760 | 38,760 | - | - | Restricted Stock Units | |
| Acumen Pharma Inc | Daniel O'Connell | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2023 | 472,500 | 472,500 | - | - | Employee Stock Option (right to buy) | |
| Acumen Pharma Inc | Daniel O'Connell | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2023 | 114,000 | 116,685 | - | 0 | Common Stock | |
| Seelos Therapeutics Inc | Daniel J. O'Connor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Seelos Therapeutics Inc | Daniel J. O'Connor | Director | Purchase of securities on an exchange or from another person at price $ 0.61 per share. | 01 Jun 2022 | 16,000 | 16,000 (0%) | 0% | 0.6 | 9,789 | Common Stock |
| W & T Offshore Inc | Daniel O. Conwill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2022 | 14,142 | 34,976 (0%) | 0% | 0 | Common Stock | |
| Acumen Pharma Inc | Daniel O'Connell | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 455,000 | 455,000 | - | - | Employee Stock Option (right to buy) | |
| Seelos Therapeutics Inc | Daniel J. O'Connor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2022 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Acumen Pharma Inc | Daniel O'Connell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2021 | 1,118 | 0 | - | - | Stock Option (Right to Buy) | |
| Acumen Pharma Inc | Daniel O'Connell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.47 per share. | 30 Nov 2021 | 1,118 | 2,685 | - | 4.5 | 4,997 | Common Stock |
| Acumen Pharma Inc | Daniel O'Connell | Director, President and CEO | 06 Jul 2021 | 123 | 0 | - | - | Series A Preferred Stock | ||
| Acumen Pharma Inc | Daniel O'Connell | Director, President and CEO | 06 Jul 2021 | 123 | 1,542 | - | - | Common Stock | ||
| Acumen Pharma Inc | Daniel O'Connell | Director, President and CEO | 06 Jul 2021 | 35 | 1,577 | - | 4.5 | 156 | Common Stock | |
| Acumen Pharma Inc | Daniel O'Connell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2021 | 35 | 0 | - | - | Warrant (Right to Buy) | |
| Acumen Pharma Inc | Daniel O'Connell | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.00 per share. | 06 Jul 2021 | 10 | 1,567 | - | 16 | 160 | Common Stock |
| W & T Offshore Inc | Daniel O. Conwill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2021 | 20,834 | 20,834 (0%) | 0% | 0 | Common Stock |